Yissum - Research Development Company of the Hebrew University

Repurposing of an Approved Drug to Increase NKp30 Ligands for Cancer Immunotherapy

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

THE USE OF “INTEGRATED STRESS RESPONSE” ACTIVATORS FOR ENHANCING B7H6-TRAGETED TREATMENTS
Project ID : 6-2018-4573

Description of the technology

Category

LifeSciences and BioTechnology

Keywords

Immunotherapy, CAR-T, BiTe, Biomarker, Immunotherapy repositioning

Current development stage

TRL4 Technology validated in lab

Our Innovation

We found and patented that approved drugs enhance the expression of NKp30 ligand. The upregulation is persistent and does not affect cell viability. We suggest to use this new modality as a combination therapy to improve efficacy of immune - therapies against broad range of cancers.

  • A method to Reduce or eliminate toxicity and side effects of the currently available and approved therapies
  • Off-patent, FDA-approved drugs with mild anti-cancer activity that can be added to the clinical protocol.
  • Major advantage over using the existing, FDA approved compounds (HDAC inhibitors) and possibly other chemotherapeutics.
  • Could be a very easily adopted as it is utilizing known and approved ISR inducing drugs.

Technology

  • Our targeted ligand is expressed on approximately 20% of tumors including solid and hematopoietic malignancies.
  • The endogenus expression is below detection in most normal cells. Thus, the ligand protein has emerged as an attractive target for cancer therapy, including but not restricted to the use of antibodies, BiTE and CAR-T applications.
  • We have identified few approved drugs that works at pharmacological levels that enhance the ligand expression.
  • Pretreatment with the approved drug may increase the ligand-tegeted immunotherapy

Opportunity

  • The proposed modality has a great impact for the therapeutic Monoclonal Antibody Market applications
  • Efficiency enhancement of currently limited application drugs against a variety of tumors without increased toxicity or side effects
  • Broad range of new therapeutic approaches to various types of human cancers.
  • New opportunities for the development of novel new combined therapy for a specific disease

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Boaz Tirosh
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • Oncology / Cancer

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.